menu
    • menu
    [{"orgOrder":0,"company":"Insilico Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"HONG KONG","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"INS018_055","moa":"TNIK","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Insilico Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Insilico Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Insilico Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Insilico Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"HONG KONG","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"INS018_055","moa":"TNIK","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Insilico Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Insilico Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Insilico Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Insilico Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"HONG KONG","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"INS018_055","moa":"TNIK","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Insilico Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Insilico Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Insilico Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Insilico Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"HONG KONG","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"INS018_055","moa":"TNIK","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Insilico Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Insilico Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Insilico Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Insilico Medicine","sponsor":"Value Partners Group","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"HONG KONG","productType":"Miscellaneous","year":"2025","type":"Series E Financing","leadProduct":"INS018_055","moa":"TNIK","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Insilico Medicine","amount2":0.11,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.11,"dosageForm":"Capsule","sponsorNew":"Insilico Medicine \/ Value Partners Group","highestDevelopmentStatusID":"8","companyTruncated":"Insilico Medicine \/ Value Partners Group"},{"orgOrder":0,"company":"Insilico Medicine","sponsor":"BHR Partners","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"HONG KONG","productType":"Miscellaneous","year":"2022","type":"Series D Financing","leadProduct":"INS018_055","moa":"TNIK","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Insilico Medicine","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.059999999999999998,"dosageForm":"Capsule","sponsorNew":"Insilico Medicine \/ BHR Partners","highestDevelopmentStatusID":"8","companyTruncated":"Insilico Medicine \/ BHR Partners"}]

    Find Clinical Drug Pipeline Developments & Deals for INS018 055

    Menu

    INS018 055

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Insilico Medicine

                            Hong Kong arrow
                            Florida Innovation
                            Not Confirmed

                            Insilico Medicine

                            Hong Kong arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : INS018_055

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : Value Partners Group

                            Deal Size : $110.0 million

                            Deal Type : Series E Financing

                            DEALS_DEV arrow-down

                            Insilico Gains $110M Series E for AI-Driven Drug Discovery

                            Details : The financing aims to fund the clinical development of company's lead product INS018_055. It is being evaluated for the treatment of Idiopathic Pulmonary Fibrosis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            March 13, 2025

                            Lead Product(s) : INS018_055

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : Value Partners Group

                            Deal Size : $110.0 million

                            Deal Type : Series E Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Insilico Medicine

                            Hong Kong arrow
                            Florida Innovation
                            Not Confirmed

                            Insilico Medicine

                            Hong Kong arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : INS018_055

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis

                            Details : INS018_055 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Idiopathic Pulmonary Fibrosis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 04, 2023

                            Lead Product(s) : INS018_055

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Insilico Medicine

                            Hong Kong arrow
                            Florida Innovation
                            Not Confirmed

                            Insilico Medicine

                            Hong Kong arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : INS018_055

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study Evaluating INS018_055 Administered Orally to Subjects with Idiopathic Pulmonary Fibrosis (IPF)

                            Details : INS018_055 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Idiopathic Pulmonary Fibrosis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 11, 2023

                            Lead Product(s) : INS018_055

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Insilico Medicine

                            Hong Kong arrow
                            Florida Innovation
                            Not Confirmed

                            Insilico Medicine

                            Hong Kong arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : INS018_055

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Insilico Medicine Receives FDA Orphan Drug Designation For Generative AI Discovered and Designed Drug for Idio...

                            Details : INS018_055 is the first anti-fibrotic small molecule inhibitor, generated by Insilico's Pharma.AI drug discovery platform, which targets major activated signaling cascades that significantly contribute to the pathogenesis idiopathic pulmonary fibrosis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 08, 2023

                            Lead Product(s) : INS018_055

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Insilico Medicine

                            Hong Kong arrow
                            Florida Innovation
                            Not Confirmed

                            Insilico Medicine

                            Hong Kong arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : INS018_055

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase I

                            Sponsor : BHR Partners

                            Deal Size : $60.0 million

                            Deal Type : Series D Financing

                            DEALS_DEV arrow-down

                            Insilico Medicine Raises $60 Million in Series D Financing to Advance Pipeline and Launch AI-powered Drug Disc...

                            Details : Capital raised in the round will further bolster Insilico's financial position and fuel the growth of its advancing pipeline, including its lead program ISM001-55 (INS018_055) which is currently in a Phase I study, and continued development of its Pharma...

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            June 06, 2022

                            Lead Product(s) : INS018_055

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase I

                            Sponsor : BHR Partners

                            Deal Size : $60.0 million

                            Deal Type : Series D Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Insilico Medicine

                            Hong Kong arrow
                            Florida Innovation
                            Not Confirmed

                            Insilico Medicine

                            Hong Kong arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : INS018_055

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase 1, Evaluate the Safety, Tolerability, and Pharmacokinetics of INS018_055 in Healthy Subjects

                            Details : INS018_055 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Idiopathic Pulmonary Fibrosis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 13, 2021

                            Lead Product(s) : INS018_055

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth